TokenPost·
FDA Extends Agios’ Mitapivat Review for Sickle Cell Disease by Three Months
The updated PDUFA goal date is Feb. 1, 2027, moved from Nov. 1, 2026. The FDA accepted the application for Priority Review in July.
More news
- TokenPostPelthos Therapeutics Shares Fall About 35% After Castle Creek Merger Deal
- CryptoSlateBOJ will more than double stock-fund sales from January
- CryptopolitanIsrael extradites Nomad exploit suspect after rejecting 'code is law' defense
- TokenPostIntel Five-Year CDS Spread Reaches 123.5 Basis Points
- TokenPostBarkin Says AI Construction Is Adding Demand Pressure for the Fed
- TokenPostBitcoin Recovers After Briefly Falling Below $77,000 Thursday